数据
资源
版本对比
免费注册
预约演示
免费注册
Vetter
’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market
2023-02-02
·
BioSpace
临床1期
临床申请
Both the US
Skokie
and European Rankweil sites address customer needs in early-phase drug development Clinical development pipeline is essential to global business strategy
Vetter Development Service
offers comprehensive expertise for in-human trial material New facility in Austria expands clinical manufacturing capacity Ravensburg, Germany and Rankweil, Austria, and
Skokie
, US, February 01, 2023 – With the increasing drug development for novel therapeutics, a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to help meet the demand for complex fill and finish solutions. And, while the stages of early drug development are challenging,
Vetter
, a globally leading Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge by offering comprehensive expert manufacturing services for clinical trials and supporting their customer products path to commercialization. A testament to this commitment is evidenced by the success of its
Skokie
facility which has already contributed to bring five new customer products to market since it began full operations in 2011, with another four expected to launch in the next months. Since the opening of the site, more than 240 customer audits have been successfully completed and the facility has performed over 45 media fills without failure. Currently,
Vetter Development Service
runs more than 80 projects in phase I and II clinical development. In the past years, the facility executed over 30 transfers from its early clinical projects to Germany for further late-stage development. “Our clinical manufacturing sites are an essential part of
Vetter
’s commercial business pipeline. And the
Skokie
site has demonstrated an impressive track record of success since its opening twelve years ago. In the last year alone, we have acquired more than 10 new customers and their promising molecules,” says Dr. Claus Feussner, Senior Vice President
Vetter Development Service
. “Overall, our ongoing investments in clinical filling capabilities are proof of
Vetter
’s consistent strategic approach to keeping abreast of the market and our focus on the important drug development needs of our customers,” adds Carsten Press, Senior Vice President Key Account Management, Supply Chain Management and Marketing at
Vetter
. Next to
Vetter Development Services
US, the CDMO’s newest clinical manufacturing site in Rankweil, Austria has increased the company’s capacity in the important field of process development as well as clinical manufacturing of Phase I and II injectables for customers. Purchased by
Vetter
in 2020, the facility has received its manufacturing authorization end of 2021 and successfully completed its first customer fills beginning of last year.
Vetter Development Services
Austria acts as a European counterpart to
Skokie
, helping to expand the CDMO‘s international presence and increase capacity. Since its opening the site’s performance has proven exceptional with fourteen projects already won and more in the pipeline. ©
Vetter Pharma International GmbH
: Supporting efficient drug development with dedicated clinical development expertise. ©
Vetter Pharma International GmbH
: Supporting efficient drug development with dedicated clinical development expertise. Find the
Vetter
press kit and more background information here. About
Vetter
Headquartered in Ravensburg, Germany,
Vetter
is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than 5,700 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small.
Vetter
services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider,
Vetter
appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about
Vetter
at . Contact
Vetter Pharma International GmbH
Markus Kirchner Corporate Spokesperson / Media Relations Eywiesenstrasse 5 88212 Ravensburg Germany Phone: +49 (0)751-3700-3729 E-mail: PRnews@vetter-pharma.com
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Vetter Senior Living
Skokie Hospital
Vetter Health Services, Inc.
[+2]
适应症
-
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务